Overview

A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

Status:
Not yet recruiting

Trial end date:
2022-07-20

Target enrollment:

Participant gender:

Summary

This is a drug-drug interaction study conducted in healthy volunteers to evaluate the pharmacokinetic effect of SHR0302 on CYP3A4, CYP2C9, CYP2C9, CYP2C19, using midazolam, s-warfarin, omeprazole, and repaglinide as probe drugs.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Midazolam
Omeprazole
Repaglinide
Vitamin K
Vitamin K 1
Warfarin